Clinical Trials

37 enrolled

Nasopharyngeal Carcinoma

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Nasopharyngeal Carcinoma

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Phase 2 Active not recruiting

Head and Neck Neoplasms

NCT05909904 2025-10-07

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

160 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

29 enrolled

Head and Neck Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

23 enrolled

Phase 2 Active not recruiting

Head and Neck Neoplasms

NCT06009861 2025-06-06

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

110 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06673693 2025-04-16

NEOSTART

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06781112 2025-01-17

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

35 enrolled

Nasopharyngeal Carcinoma

NCT06728618 2024-12-11

OSCC

28 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

46 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06366945 2024-04-16

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

85 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

39 enrolled

Nasopharyngeal Carcinoma

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05862168 2023-07-17

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05343325 2022-12-29

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT05595590 2022-10-27

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

20 enrolled

Head and Neck Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT04921995 2022-04-04

RETICULA-NPC

40 enrolled

Nasopharyngeal Carcinoma

NCT04814069 2021-03-24

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

38 enrolled